1. Home
  2. AI vs SRPT Comparison

AI vs SRPT Comparison

Compare AI & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C3.ai Inc.

AI

C3.ai Inc.

HOLD

Current Price

$10.79

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

HOLD

Current Price

$20.72

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AI
SRPT
Founded
2009
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.0B
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
AI
SRPT
Price
$10.79
$20.72
Analyst Decision
Hold
Hold
Analyst Count
14
29
Target Price
$14.00
$25.85
AVG Volume (30 Days)
5.0M
3.0M
Earning Date
05-27-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.99
Revenue
$250,268,000.00
$2,198,237,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$6.84
Revenue Growth
N/A
15.58
52 Week Low
$7.68
$14.68
52 Week High
$20.22
$25.32

Technical Indicators

Market Signals
Indicator
AI
SRPT
Relative Strength Index (RSI) 63.89 54.93
Support Level $9.73 $20.12
Resistance Level $11.94 $23.70
Average True Range (ATR) 0.50 1.55
MACD 0.02 -0.14
Stochastic Oscillator 89.18 50.28

Price Performance

Historical Comparison
AI
SRPT

About AI C3.ai Inc.

C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions, namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications; C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications; and C3 Generative AI, which combines the utility of large language models. Geographically, the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Share on Social Networks: